CureVac (CVAC) Projected to Post Quarterly Earnings on Thursday

CureVac (NASDAQ:CVAC - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 22nd. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $4.27 million for the quarter.

CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The company had revenue of $15.44 million during the quarter, compared to analyst estimates of $6.40 million. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Price Performance

CureVac stock traded up $0.41 during trading on Tuesday, reaching $4.28. The company had a trading volume of 1,602,676 shares, compared to its average volume of 796,443. The firm's 50-day simple moving average is $3.18 and its 200 day simple moving average is $3.26. CureVac has a 1-year low of $2.37 and a 1-year high of $5.28. The firm has a market capitalization of $960.17 million, a PE ratio of 7.78 and a beta of 2.43. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.

Wall Street Analysts Forecast Growth

CVAC has been the topic of several recent research reports. JMP Securities reaffirmed a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research note on Friday, February 14th. UBS Group lowered their target price on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC raised its holdings in CureVac by 10.3% in the 1st quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock valued at $5,033,000 after buying an additional 169,947 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in CureVac in the 1st quarter valued at about $142,000. Finally, Integrated Wealth Concepts LLC raised its holdings in CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after buying an additional 3,000 shares during the period. Institutional investors and hedge funds own 17.26% of the company's stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.